Mike Lehmicke – VJRegenMed

Looking ahead to the Cell & Gene Meeting on the Mediterranean 2021

admin_vjr_user — Sat, 10 Apr 2021 10:58:01 +0000

The Cell & Gene Meeting on the Mediterranean 2021 is being held virtually this year. Mike Lehmicke, Director of Science & Industry Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., shares his thoughts on the benefits of the virtual format, as well as some of the key sessions to look out for. The conference will feature panel discussions dedicated to the development of advanced therapy medicinal products (ATMPs) for specific indications, including in neurological and ophthalmologic diseases, as well a session on next generation applications of induced pluripotent stem cell (iPSC) technologies. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

The challenges of CMC in cell and gene therapies

admin_vjr_user — Sat, 10 Apr 2021 10:58:00 +0000

Mike Lehmicke, Director of Science & Industry Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., discusses the challenges faced by the advanced therapy medicinal products (ATMP) field as a result of chemistry, manufacturing and control (CMC) regulations. ARM works with regulatory bodies and stakeholders to overcome CMC issues and aims to improve the clarity with which requirements are communicated to prevent them delaying commercialization. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

Looking ahead in the cell & gene therapy sector

admin_vjr_user — Sat, 10 Apr 2021 10:57:59 +0000

Mike Lehmicke, Director of Science & Industry Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., discusses some of the exciting recent developments in the cell and gene therapy sector, including advancements made in allogeneic therapies for oncology, the potential induced pluripotent stem cell (iPSC) technology holds and how novel manufacturing technologies and process analytics could help drive the field forward in the future. He also discusses the impact of the COVID-19 and what the field can learn from the pandemic to accelerate progress in cell and gene therapy. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

A-Gene: a best practice guide for gene therapy development

admin_vjr_user — Sat, 10 Apr 2021 10:57:57 +0000

Mike Lehmicke, Director of Science & Industry Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., introduces A-Gene, a best practice guide for developing and manufacturing gene therapy products. This open-source educational resource, currently being developed by ARM, is intended to be used as a reference guide for companies in gene therapy sector and aims to establishing consensus on best practice within the industry and help drive advancement. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.